The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications

Preclinical proof-of-concept, feasibility and efficacy studies in lower animals resulted in the accumulation of data that served as a backbone for clinical trials with the recombinant, osteogenic bone morphogenetic protein-2 (BMP-2). Among the important observations was the dependence of dose and carrier on the outcome for osseous union in relation to the animal model used. Clinical outcome data for spinal applications indicate better overall results compared with traditional controls that utilised autogenous iliac crest bone graft for fusion. Parameters include less blood loss, less operating room time and costs, better fusion outcomes and increased patient satisfaction. At this juncture, the long journey from the identification of BMP-2 in demineralised bone fraction to FDA approval for use in a singular orthopaedic application has been completed. It has been demonstrated to be safe, efficacious and cost-effective, leading to increased patient satisfaction and improved clinical outcome.

[1]  G. Finerman,et al.  Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein. A preliminary report. , 1988, Clinical orthopaedics and related research.

[2]  K. Takaoka,et al.  Repair of segmental defects in rabbit humeri with titanium fiber mesh cylinders containing recombinant human bone morphogenetic protein-2 (rhBMP-2) and a synthetic polymer. , 2002, Journal of biomedical materials research.

[3]  S. Boden,et al.  The Use of rhBMP-2 in Interbody Fusion Cages: Definitive Evidence of Osteoinduction in Humans: A Preliminary Report , 2000, Spine.

[4]  M. Urist,et al.  Bone morphogenetic protein augmentation grafting of resistant femoral nonunions. A preliminary report. , 1988, Clinical orthopaedics and related research.

[5]  J. Wozney,et al.  Augmentation of autograft using rhBMP-2 and different carrier media in the canine spinal fusion model. , 1997, Journal of spinal disorders.

[6]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[7]  S. Boden,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 to Achieve Posterolateral Lumbar Spine Fusion in Humans: A Prospective, Randomized Clinical Pilot Trial 2002 Volvo Award in Clinical Studies , 2002, Spine.

[8]  Adam J Starr,et al.  Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures. , 2003, The Journal of bone and joint surgery. American volume.

[9]  J. Michael Kabo,et al.  Histologic Evaluation of the Efficacy of rhBMP-2 Compared With Autograft Bone in Sheep Spinal Anterior Interbody Fusion , 2002, Spine.

[10]  M. Urist,et al.  Bone: Formation by Autoinduction , 1965, Science.

[11]  H. Sandhu,et al.  Use of Recombinant Human Bone Morphogenetic Protein-2 in Spinal Fusion Applications , 2002, Spine.

[12]  S. Boden,et al.  Posterolateral Lumbar Intertransverse Process Spine Arthrodesis With Recombinant Human Bone Morphogenetic Protein 2/Hydroxyapatite‐Tricalcium Phosphate After Laminectomy in the Nonhuman Primate , 1999, Spine.

[13]  S. Boden,et al.  Laparoscopic anterior spinal arthrodesis with rhBMP-2 in a titanium interbody threaded cage. , 1997, Journal of spinal disorders.

[14]  Koichiro Takahashi,et al.  Bone regeneration by recombinant human bone morphogenetic protein-2 and a novel biodegradable carrier in a rabbit ulnar defect model. , 2003, Biomaterials.

[15]  M. Urist,et al.  The bone induction principle. , 1967, Clinical orthopaedics and related research.

[16]  J M Toth,et al.  Experimental Spinal Fusion With Recombinant Human Bone Morphogenetic Protein-2 Without Decortication of Osseous Elements , 1997, Spine.

[17]  W. Hutton,et al.  Delivery of Recombinant Human Bone Morphogenetic Protein-2 Using a Compression-Resistant Matrix in Posterolateral Spine Fusion in the Rabbit and in the Non-Human Primate , 2002, Spine.

[18]  K. Johnson,et al.  Evaluation of recombinant human bone morphogenetic protein‐2 as a bone‐graft substitute in a canine segmental defect model , 2000, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[19]  E. Wang,et al.  Healing segmental femoral defects in sheep using recombinant human bone morphogenetic protein. , 1993, Clinical orthopaedics and related research.

[20]  R. Delamarter,et al.  Effective Doses of Recombinant Human Bone Morphogenetic Protein‐2 in Experimental Spinal Fusion , 1996, Spine.

[21]  T. Murakami,et al.  Injectable magnetic liposomes as a novel carrier of recombinant human BMP-2 for bone formation in a rat bone-defect model. , 2003, Journal of biomedical materials research. Part A.

[22]  V. Rosen,et al.  Purification and characterization of other distinct bone-inducing factors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Urist,et al.  Solubilized and insolubilized bone morphogenetic protein. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Marone,et al.  Posterolateral intertransverse process spinal arthrodesis with rhBMP-2 in a nonhuman primate: important lessons learned regarding dose, carrier, and safety. , 1999, Journal of spinal disorders.

[25]  S. Govender,et al.  Staged reduction and stabilisation in chronic atlantoaxial rotatory fixation. , 2002, The Journal of bone and joint surgery. British volume.